ClinicalTrials.gg
Not yet recruitingNCT07110233Updated Oct 6, 2026

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma

An interventional study of TheraSphere® Yttrium-90 microspheres and Health Related Quality of Life Questionnaires (HRQOL) in Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma and Hepatocellular Cancer, sponsored by University of California, San Francisco. Not yet recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Planned enrollment
254th of 775
64 · median 36
Started
2026
with 35 others
No phase
124 of 926
26 open now
Primary completion
2029-03
later than 201 of 244 live
Registered
882nd of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 254th largest by planned enrollment of the 775 interventional ones that give a count, is one of 36 that started in 2026, is one of 124 with no phase, reaches primary completion later than 201 of the 244 other live ones, and was the 882nd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with unresectable Barcelona clinic liver cancer (BCLC) stage A disease.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the objective response rate (ORR) after radiation segmentectomy in participants with BCLC Stage A HCC and 1) a single solitary tumor measuring 2-5 centimeters (cm) and 2) 2 or 3 lesions each ≤ 3 cm.

II. To assess the safety of radiation segmentectomy.

SECONDARY OBJECTIVES:

I. To evaluate transplant-free survival.

II. To evaluate progression-free survival.

III. To evaluate the quality of life of participants.

IV. To evaluate the best imaging response. V. To determine the proportion of participants who remain active on the wait list for liver transplant and eventually are transplanted.

VI. The evaluate the number of participants that need additional treatment after TheraSphere® administration.

VII. Complete pathologic response (CPN) on liver explants among participants who underwent liver transplant.

Participants will undergo a single TheraSphere® administration and followed for quality-of-life outcomes and survival for up to 3 years after treatment. Participants will be censored at time of future transplant or if death occurs at any time after treatment.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Unresectable Hepatocellular Carcinoma
  • Hepatocellular Cancer
  • Hepatocellular Carcinoma Non-resectable
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have histologically or imaging-confirmed confirmed HCC.
  2. Group 1: Solitary tumor measuring 2-5 cm Or Group 2: 2-3 tumors each ≤ 3 cm in diameter.
  3. No prior therapy to target tumor(s).
  4. Not a candidate for surgical resection or thermal ablation after multidisciplinary assessment.
  5. Age ≥22 years.
  6. (ECOG) performance status = 0 or 1.
  7. Demonstrated adequate organ function as defined below:

    1. Total ≤3.0 mg/dL, unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits.
    2. (AST)/serum glutamic-oxaloacetic transaminase (SGOT) ≤5 X institutional .
    3. alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) ≤5 X institutional upper limit of normal.
    4. Creatinine (GFR) > 30 ml/min.
  8. score ≤ B7
  9. Albumin-bilirubin (ALBI) score 1-2
  10. Participants who have received systemic therapy for HCC will be excluded from the trial.
  11. Ability to understand a written document, and the willingness to sign it.
  12. (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  13. Participants with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.

Exclusion criteria

Exclusion Criteria:

  1. Macrovascular tumor invasion or infiltrative appearance of hepatocellular carcinoma.
  2. History of severe allergy to iodinated contrast agents despite appropriate premedication.
  3. Is currently receiving any other anti-cancer agents and any previous therapy with a device that uses Y90 as the radioisotope.
  4. Symptomatic heart failure or severe valvular insufficiency.
  5. Symptomatic pulmonary hypertension or lung disease.
  6. Symptomatic ascites.
  7. Severe uncontrolled coagulopathy (INR) ≥ 3.0 or ≤ 20,000.
  8. Main vein thrombosis (portal vein, both bland and tumor thrombus). Note: Less than lobar portal vein thrombosis is allowable only if the thrombus is bland.
  9. Pregnant women are excluded from this study because TheraSphere emits radiation with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with TheraSphere, breastfeeding should be discontinued if the mother is treated with TheraSphere.
  10. Lung-shunt fraction (LSF) resulting in anticipated lung dose of >30 Gray (Gy).
  11. History of sphincterotomy, biliary-enteric anastomosis, or other biliary tract instrumentation. Note: Prior cholecystectomy with or without bile duct exploration is permitted.
  12. Tumor perfused by extrahepatic collateral arteries.
  13. Prior partial hepatectomy.
  14. Psychiatric illness, other significant medical illness, or social situation which, in the investigator's opinion, would limit compliance or ability to comply with study requirements.
  15. History of or current extrahepatic cancer.
  16. Pulmonary insufficiency (defined by an arterial oxygen pressure (Pa,O2) of \< 60 mmHg, or oxygen saturation (Sa,O2) of \< 90%).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Group 1. TheraSphere® Yttrium-90 microspheres

    Participants with a single tumor measuring 2-5 cm will receive one dose of TheraSphere® \>250 Gy, and ideally \> 400 Gy at the treating physician's discretion. Participants will be monitored for safety and complete quality of life questionnaires.

    Device: TheraSphere® Yttrium-90 microspheres · Other: Health Related Quality of Life Questionnaires (HRQOL)

  • Experimental
    Group 2. TheraSphere® Yttrium-90 microspheres

    Participants with 2-3 tumors ≤ 3 cm in diameter (T2 disease) will receive one dose of TheraSphere® \>250 Gy, and ideally \> 400 Gy at the treating physician's discretion. Participants will be monitored for safety and complete quality of life questionnaires.

    Device: TheraSphere® Yttrium-90 microspheres · Other: Health Related Quality of Life Questionnaires (HRQOL)

Interventions

  • DeviceTheraSphere® Yttrium-90 microspheres

    Administered intra-arterially

    Also known as: TheraSphere®, Yttrium-90 microspheres, Microspheres Radionuclide

  • OtherHealth Related Quality of Life Questionnaires (HRQOL)

    Surveys administered

    Also known as: HRQOL Questionnaires

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) by mRECIST

    The objective response rate (ORR) after radiation segmentectomy in participants will be evaluated using a modified Response Evaluation Criteria in Solid Tumors (mRECIST) based on the best tumor response where Complete Response (CR) is defined as the disappearance of any intratumoral arterial enhancement in all target lesions, Partial Response (PR) is defined as a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions, Stable Disease (SD) is defined as any cases that do not qualify for either partial response or progressive disease, and Progressive Disease (PD) is defined as an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started.

    Time frame: Up to 6 months

  2. Percentage of participants with treatment-related adverse events

    The percentage of participants with grade 3 or greater, treatment-related adverse events as classified by NCI Common Terminology Criteria for Adverse Events (CTCAE) will be reported.

    Time frame: Up to 6 months

Secondary outcomes

  1. Median time from TheraSphere administration to transplant

    Transplant-free survival is defined as the time to transplant in months from TheraSphere administration until transplant or death by any cause using the Kaplan-Meier estimator and 90% confidence intervals.

    Time frame: Up to 3 years

  2. Median time to disease progression

    Progression-free survival is defined as the time to tumor progression (in-field, distant intrahepatic, extrahepatic) based on mRECIST in months from TheraSphere administration until disease progression or death by any cause using the Kaplan-Meier estimator and 90% confidence intervals will be reported.

    Time frame: Up to 3 years

  3. Changes in mean Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep) survey results over time

    The FACT-Hep is a 45-item self-report instrument developed to assess health-related quality of life (HRQoL) in persons diagnosed with hepatobiliary cancers and consists of the Functional Assessment of Cancer Therapy scale (FACT-G) which is a 27-item questionnaire designed to measure four domains of HRQOL in cancer patients: Physical, social, emotional, and functional well-being and also includes a Hepatobiliary Cancer Subscale (HCS) which consists of an additional 18-items focusing on disease-specific symptoms such as back and stomach pain, gastrointestinal issues, anorexia, weight loss, and jaundice. Each item response score ranges from 0 (not at all) to 4 (very much) with a total score range from 0-180. The higher the score, the better the HRQoL. The change in mean scores over time will be reported.

    Time frame: Up to 6 months

  4. Changes in mean EuroQol five-dimensional Questionnaire (EQ-5D) survey results over time

    EQ-5D is a standardized instrument for measuring generic health status. The health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The respondents self-rate their level of severity for each dimension by selecting one of the following responses: no problems (0), slight problems (1), mild problems (2), moderate problems (3), or severe problems (4) with a particular dimension. Lower scores indicate less issues/problems with that particular health dimension. The change in mean scores over time will be reported.

    Time frame: Up to 6 months

  5. Best observed tumor response by mRECIST.

    Best imaging response at 1 year will be determined based on mRECIST criteria among imaging follow up within 1 year of treatment.

    Time frame: Up to 1 year

  6. Proportion of participants on an active liver transplant waitlist who receive a transplant

    Participants status on the transplant list will be recorded and the proportion of them among all enrolled participants will be reported.

    Time frame: Up to 3 years

  7. Proportion of participants requiring additional therapies

    The proportion of participants that need subsequent loco-regional therapies as deemed clinically indicated after TheraSphere administration will be reported.

    Time frame: Up to 3 years

  8. Proportion of participants with Complete pathologic response (CPN)

    The proportion of participants who underwent a liver transplant and demonstrated CPN post-transplant will be reported.

    Time frame: Up to 3 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2029, 29 months later.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 29 months is below that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 7, 2025
StartEst.
Oct 1, 2026
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07110233
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Oct 1, 2026 (estimated)
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Maya Aslam
Contact
Maya.Aslam@ucsf.edu
(415) 514-8987
Ryan Lokken, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion